Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: HRMY stock price vs CROX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CROX's multiple
Needs CROX P/E.
Implied fair value · at HRMY's multiple
Needs EPS (TTM) is negative, HRMY P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HRMY FY 2025 (ended Dec 31, 2025) · CROX FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
HARMONY BIOSCIENCES HOLDINGS, INC. · implied price per share
Bear
$42.25
Base
$49.71
Bull
$57.16
CROCS, INC. · implied price per share
Bear
$34.61
Base
$40.72
Bull
$46.82
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.19x
0.01x
Net debt / EBITDA
Leverage against operating earnings
-2.20x
-0.32x
Cash and equivalents
Liquid reserves on the balance sheet
$775.34M
$130.35M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
HRMY vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
HRMY vs SUPN
Intra-Cellular Therapies, Inc.
HRMY vs ITCI
ACADIA PHARMACEUTICALS INC
HRMY vs ACAD
Vanda Pharmaceuticals Inc.
HRMY vs VNDA
LivaNova PLC
HRMY vs LIVN
DECKERS OUTDOOR CORP
HRMY vs DECK
SKECHERS USA INC
HRMY vs SKX
Designer Brands Inc.
HRMY vs DBI
NIKE, Inc.
HRMY vs NKE
CALERES INC
HRMY vs CAL
$163.66M
$6.64M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe HRMY’s growth and margin profile can remain well above CROX’s, then hold or selectively accumulate HRMY rather than using CROX-based valuation as the main benchmark, because HRMY’s superior profitability and ROIC justify a premium despite the current 37.9% downside to CROX-implied price.
At the current price of $37.26, HRMY trades 37.9% above the CROX-based implied price of $23.13, suggesting a meaningful relative-valuation premium on this specific basis. However, that CROX anchor is complicated by HRMY’s much stronger profitability and growth profile versus CROX, so the gap may reflect fundamentals as much as mispricing.
Supporting Metrics
